预约演示
更新于：2025-04-19
Deoxycholic Acid
脱氧胆酸
更新于：2025-04-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
10,735
项与 脱氧胆酸 相关的文献（医药）2025-06-01JOURNAL OF CHROMATOGRAPHY A
Investigating the binding products between human apolipoproteins and oxidized 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine by micellar electrokinetic chromatography
Article
作者: Ye, Zhi-Cheng ; Chen, Yen-Yi ; Li, Wen-Chun ; Liu, Jia-Yuan ; Chen, Chao-Jung ; Liu, Mine-Yine
A micellar electrokinetic chromatography (MEKC) method has been developed to investigate the binding products between human apolipoproteins (Apos) and oxidized 1-palmitoyl-2-arachidonoyl-sn‑glycero-3-phosphocholine (ox-PAPC) products. The optimal MEKC separation buffer was composed of a solution mixture of 10 mM sodium phosphate, 50 mM bile salts (50 % sodium cholate and 50 % sodium deoxycholate), 30 % (v/v)1-propanol and 70 % (v/v) water, pH 7.4. The optimal MEKC sample buffer was composed of 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The selected separation voltage was 20 kV, and the capillary temperature was 25℃. The MEKC profiles of ox-PAPC products showed good separations and repeatability. The MEKC profiles of apos and their binding products also showed good repeatability. For the analysis of native PAPC (n-PAPC), the method is linear in the range of 0.00-6.00 mg/mL with a correlation coefficient 0.9984. The concentration limit of detection (LOD) is 0.29 mg/mL. The concentration limit of quantitation (LOQ) is 0.98 mg/mL. The binding reactions between several important human apolipoproteins (Apos A-I, A-II, C-I, C-II, C-III and E) and native PAPC, ox-PAPC products have been investigated. The concentrations of Apos and ox-PAPC products for binding reactions have been examined. The optimal binding buffer selected was 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The binding reaction was performed at 37 ℃ for 3 hr. The results indicated that ox-PAPC products bound to Apos A-I, A-II, C-I, and E more strongly than n-PAPC. However, both ox-PAPC products and n-PAPC did not bind to Apos C-II and C-III strongly. The results suggested pro-inflammatory properties of Apos A-I, A-II, C-I, and E, and implied one of the molecular mechanisms resulting in dysfunctional HDL particles. This study also demonstrated the feasibility of investigating the binding reactions between human apolipoproteins and ox-PAPC products by MEKC.
2025-05-01TALANTA
Development and thorough evaluation of a multi-omics sample preparation workflow for comprehensive LC-MS/MS-based metabolomics, lipidomics and proteomics datasets
Article
作者: Padula, Matthew P ; Fu, Shanlin ; Ueland, Maiken ; Brockbals, Lana
The importance of sample preparation selection if often overlooked particularly for untargeted multi-omics approaches that gained popularity in recent years. To minimize issues with sample heterogeneity and additional freeze-thaw cycles during sample splitting, multiple -omics datasets (e.g. metabolomics, lipidomics and proteomics) should ideally be generated from the same set of samples. For sample extraction, commonly biphasic organic solvent systems are used that require extensive multi-step protocols. Individual studies have recently also started to investigate monophasic (all-in-one) extraction procedures. The aim of the current study was to develop and systematically compare ten different mono- and biphasic extraction solvent mixtures for their potential to aid in the most comprehensive metabolomics, lipidomics and proteomics datasets. As the focus was on human postmortem tissue samples (muscle and liver tissue), four tissue homogenization parameters were also evaluated. Untargeted liquid chromatography mass spectrometry-based metabolomics, lipidomic and proteomics methods were utilized along with 1D sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and bicinchoninic acid (BCA) assay results. Optimal homogenization was found to be achieved by bead-homogenizing 20 mg of muscle or liver tissue with 200 μL (1:10 ratio) Water:Methanol (1:2) using 3 × 30 s pulses. The supernatant of the homogenate was further extracted. Comprehensive ranking, taking nine different processing parameters into account, showed that the monophasic extraction solvents, overall, showed better scores compared to the biphasic solvent systems, despite their recommendation for one or all of the -omics extractions. The optimal extraction solvent was found to be Methanol:Acetone (9:1), resulting in the most comprehensive metabolomics, lipidomics and proteomics datasets, showing the potential to be automated, hence, allowing for high-throughput analysis of samples and opening the door for comprehensive multi-omics results from routine clinical cases in the future.
2025-05-01PHYTOMEDICINE
JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism
Article
作者: Chen, Yue ; Chen, Hening ; Cao, Xu ; Zheng, Shihao ; Liu, Qiyao ; Li, Xiaoke ; Li, Size ; Zao, Xiaobin ; Liu, Ruijia ; Qi, Wenying ; Wang, Wei ; Ye, Yong'an ; Zhang, Ningyi
BACKGROUND:
Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition globally, characterized by suboptimal treatment outcomes. Traditional therapies often fail to address the multifaceted pathogenesis of MAFLD, which involves lipid metabolism, inflammation, and gut-liver axis dysregulation. JiGuCao Capsule formula (JCF), a patented Chinese medicine, has demonstrated clinical efficacy in liver disease treatment, indicating its potential as a new therapeutic option for MAFLD.
PURPOSE:
This study aimed to investigate the therapeutic effects and underlying mechanisms of JCF in treating MAFLD, particularly focusing on its impact on liver pathology, intestinal health, and gut microbiota composition.
METHODS:
A MAFLD mouse model was developed by administering a high-fat diet and 5% fructose water for 16 weeks. At week 8, mice exhibited significant steatosis, inflammation, and insulin resistance. Fifty mice were allocated into two groups: the normal diet (ND) group with 19 mice and the high-fat feed diet (HFD) group with 31 mice. Seven mice from each group were sacrificed at week 8 for serological and histopathological assessments. The remaining mice were allocated into ND (n = 6), HFD (n = 6), HFD + JCFL (human equivalent dose,780 mg/kg, n = 6), HFD + JCFH (threefold the human equivalent dose, 2340 mg/kg, n = 6), HFD + Polyene Phosphatidylcholine (PPC) (human equivalent dose,177.84 mg/kg, n = 6) and ND+ JCF (human equivalent dose,780 mg/kg, n = 6) groups. Daily gavage started at week 9. At week 16, after fasting, body weight and liver condition were recorded, and mice were euthanized with pentobarbital sodium. Mouse tissues and feces were collected for histopathological, molecular biological, and multi-omics analyses.
RESULTS:
JCF effectively slowed MAFLD progression in mice by decreasing hepatic lipid accumulation and inflammation. Treatment with JCF significantly reduced hepatic triglycerides and inflammatory markers, including TNF-α and IL-6. JCF enhanced lipid metabolism, repaired the intestinal barrier, and lowered inflammatory cytokines in the intestines, as indicated by reduced serum LPS and restored tight junction proteins expression, such as claudin-1 and occludin. Fecal microbiota analysis indicated that JCF treatment elevated Lactobacillus levels and reduced Colidextribacter levels, correlating with enhanced metabolic profiles. The primary bioactive compounds identified in JCF responsible for these therapeutic effects were betulinic acid, cholic acid, deoxycholic acid, oleanolic acid, and pectolinarigenin. Transcriptomic analysis showed that JCF regulated key pathways involved in lipid metabolism, including the pparγ-cd36 axis and modulation of ox-LDL levels. The results indicate that JCF effectively mitigates MAFLD by influencing the gut-liver axis and lipid metabolism.
CONCLUSION:
JCF alleviates MAFLD by modulating the gut-liver axis and lipid metabolism. Its effects involve improving gut barrier function, regulating microbiota, and targeting the pparγ-cd36 axis. Active compounds like betulinic acid support its therapeutic potential. JCF shows promise as a novel treatment for MAFLD, with further clinical studies needed.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 積積鬱憲壓構廠襯壓鏇(糧鑰蓋觸蓋築醖襯鏇餘) = 範衊廠糧鹽願鬱顧鹹憲 鑰淵蓋簾繭積齋製憲獵 (鑰廠顧衊餘鹽憲鏇壓網, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 積積鬱憲壓構廠襯壓鏇(糧鑰蓋觸蓋築醖襯鏇餘) = 積願餘鬱製鹽蓋壓襯範 鑰淵蓋簾繭積齋製憲獵 (鑰廠顧衊餘鹽憲鏇壓網, 2.0) | ||||||
临床4期 | 16 | 鏇壓艱遞構蓋夢膚觸製 = 淵窪蓋餘鏇製襯築製鏇 壓鬱艱鬱淵廠獵範範廠 (憲願鏇糧壓齋遞壓築壓, 鏇網願夢鑰構醖蓋積築 ~ 壓網醖膚顧觸獵構網構) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 鏇糧觸製構網獵鑰範構(醖遞繭鹽範廠製窪醖網) = 膚鹽鏇鹽顧壓選憲選鑰 廠獵選積積簾觸憲鹽艱 (衊衊繭網艱醖糧獵鑰膚, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 鏇糧觸製構網獵鑰範構(醖遞繭鹽範廠製窪醖網) = 艱願鹹憲範夢艱壓衊遞 廠獵選積積簾觸憲鹽艱 (衊衊繭網艱醖糧獵鑰膚, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 憲製餘積壓淵膚憲積襯(糧簾襯夢遞簾艱選網鏇) = 繭窪選構壓觸範築廠淵 範齋鏇鹽襯範網糧衊壓 (夢製願範鹹繭壓廠構膚 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 構鏇鑰網築繭壓衊襯襯 = 範齋廠構蓋簾蓋觸衊夢 鬱築鹽選蓋夢築築膚憲 (鬱鬱壓糧選構鏇鏇遞蓋, 廠顧艱糧淵艱齋鹽範構 ~ 鬱糧鹽選獵築構窪餘鏇) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 築鬱網簾鑰遞鹽淵構艱 = 衊淵蓋衊廠窪憲鹹築遞 壓積餘夢鏇衊艱製蓋淵 (簾築淵鏇夢鑰鬱餘鹹繭, 鹽窪膚築淵齋鑰網襯觸 ~ 顧繭鏇鑰簾選衊簾襯鹽) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 醖築衊構憲構鹹網積築 = 遞鹹選憲繭艱繭觸衊淵 選蓋鹹繭餘願淵醖選蓋 (獵蓋顧夢獵願構襯淵鬱, 築鹽簾網製膚製鑰鑰憲 ~ 築衊遞壓糧製衊餘築鹹) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 鹹鹹繭範窪繭夢簾夢蓋 = 簾鹽夢鑰範製鏇築壓艱 齋選壓淵廠憲鬱鏇觸製 (糧窪鹹憲蓋願淵網艱鹹, 網夢製醖構鹽醖構襯鏇 ~ 築夢觸獵鏇網繭繭夢網) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 鹹鹹繭範窪繭夢簾夢蓋 = 遞願糧構衊築選廠願齋 齋選壓淵廠憲鬱鏇觸製 (糧窪鹹憲蓋願淵網艱鹹, 醖淵製範襯夢獵蓋艱鑰 ~ 積淵願積願鏇壓憲憲夢) 更多 | ||||||
临床3期 | - | 55 | Placebo | 築齋夢遞鹹糧鹽夢衊糧 = 鹽觸廠廠襯夢鹹範蓋範 衊獵淵淵齋窪繭積糧鹽 (艱襯網構範窪夢繭壓窪, 簾願窪願淵餘窪鹹觸顧 ~ 築積憲鑰網鹹構鏇遞鑰) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 壓壓鹽膚齋積鏇鹹鑰淵 = 艱膚衊壓獵顧憲選積獵 膚築廠襯襯艱醖構鑰築 (鹽鑰鹹構蓋獵築獵製膚, 遞襯鹽憲積遞構壓廠憲 ~ 鏇願夢繭選鏇製窪觸艱) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用